AP NEWS

QIAGEN and NeuMoDx Announce Strategic Partnership to Offer Next-Generation Systems for Fully Integrated Molecular Diagnostic Testing

September 17, 2018

HILDEN, Germany & ANN ARBOR, Mich.--(BUSINESS WIRE)--Sep 17, 2018--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx Molecular, Inc. today announced a strategic partnership to commercialize two new fully integrated systems for automation of PCR (polymerase chain reaction) testing. These next-generation systems are specifically designed to help clinical molecular diagnostic laboratories process increasing test volumes and deliver more rapid insights on a broad range of diseases.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180916005014/en/

NeuMoDx 288 (Photo: Business Wire)

Under the agreement, QIAGEN will initially distribute the NeuMoDx™ 288 (high-throughput version) and NeuMoDx™ 96 (mid-throughput version) in Europe and other major markets worldwide outside of the United States. NeuMoDx will cover the United States directly. Additionally, the companies are collaborating to implement certain QIAGEN chemistries on the NeuMoDx systems. The two companies have also entered into a merger agreement under which QIAGEN can acquire all NeuMoDx shares not currently owned by QIAGEN at a predetermined price of approximately $234 million (QIAGEN currently owns about 19.9% of NeuMoDx), subject to the achievement of certain regulatory and operational milestones.

QIAGEN intends to begin commercialization of the NeuMoDx systems at the European Society of Clinical Virology (ESCV) congress (September 23-26 in Athens, Greece) with an initial assay menu based on the first two CE-IVD marked assays for Group B Streptococcus (GBS) and Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) infections. The NeuMoDx systems offer a growing menu of relevant in vitro diagnostic (IVD) tests and the ability to process both commercial and laboratory-developed tests (LDTs) in the most flexible and efficient manner. LDTs, which account for an important number of test requests and volumes, are IVD tests designed by clinical labs for their own use.

Please find the full press release here

View source version on businesswire.com:https://www.businesswire.com/news/home/20180916005014/en/

CONTACT: QIAGEN

Investor Relations

John Gilardi, +49 2103 29 11711

Dr. Sarah Fakih, +49 2103 29 11457

ir@QIAGEN.com

or

Public Relations

Dr. Thomas Theuringer, +49 2103 29 11826

Robert Reitze, +49 2103 29 11676

pr@QIAGEN.com

or

NEUMODX

info@neumodx.com

KEYWORD: UNITED STATES EUROPE NORTH AMERICA MICHIGAN GERMANY NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY OTHER HEALTH GENERAL HEALTH

SOURCE: QIAGEN N.V.

Copyright Business Wire 2018.

PUB: 09/17/2018 01:31 AM/DISC: 09/17/2018 01:31 AM

http://www.businesswire.com/news/home/20180916005014/en

AP RADIO
Update hourly